Nutrient Signaling and Metabolism at the Helm of Cardiometabolic Diseases

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Biochemistry and Molecular Biology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3075

Special Issue Editors


E-Mail Website
Guest Editor
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Interests: metabolism; gene transcription; epigenetics; cell signaling; obesity; cardiovascular disease

E-Mail Website
Guest Editor
Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
Interests: nutrient signaling; muscle metabolism; obesity; cancer metabolism; metabolic flux
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiometabolic disease (CMD) is a comprehensive term used to describe the increased risk for cardiovascular diseases arising due to a group of interrelated systemic metabolic abnormalities. CMD is one of the leading causes of death worldwide and its heterogeneity makes it difficult to cure this debilitating health problem. These are linked with a cluster of risk factors that include, but are not limited to, genetic, behavioral, and environmental factors, such as obesity, diet, physical inactivity, hypertension, and air pollution.

Systemic metabolism involves a vast number of pathways that regulate nutrient intake and utilization, and requires the participation and well-orchestrated crosstalk between multiple organs to maximize the efficiency of the processes. Coordination of metabolic flux between different tissues is based on effective communication by a multitude of secretory or paracrine factors including hormones, small molecules, and lipids. Disruption of one or more of these signaling axes can impact the metabolic events at the molecular, and, therefore, systems-level contributing to the complexity of CMD.

In this Special Issue of Biology, our emphasis is to provide the readers with an understanding of new strategies of cellular maladaptation in response to disrupted nutrient metabolism and signaling resulting in CMD. The goal is to evaluate the risk pathways associated with nutrient signaling dysfunction at cellular and systemic levels that will allow identification of novel therapeutic strategies for CMD. Articles of all categories (original research articles, reviews) pertaining to basic/fundamental science, in vivo studies, clinical/translational studies and meta-analyses will be considered for peer-review. Proof-of-concept and technical (method development) studies will be given consideration. Potential topics include, but are not limited to:

  1. Nutrient (macro or micro) sensing, signaling, and metabolism leading to metabolic abnormalities precipitating in CMD (including amino acids, fatty acids, sugars, vitamins, etc.);
  2. Nutrient trafficking and its impact on the development of CMD or any co-morbidities precipitating in CMD (including obesity, glucose and/or insulin sensitivity, inflammation);
  3. Transcriptional (including post-transcriptional), epigenetic and translational (including post-translational) mechanisms regulating nutrient metabolism associated with the development of CMD;
  4. Inter-organ and intercellular crosstalk facilitated by nutrients and/or secretory hormones that can influence cardiometabolic health (e.g., adipose tissue, skeletal muscle, hepatic, neural, and renal axes, etc.);
  5. Small molecules and bioactive compounds targeting different nutrient signaling pathway components (including amino acids, fatty acids, sugars, etc.) that have potential therapeutic implications in the treatment of CMD.

Through your scientific contributions to this issue, we hope to enhance and improve the knowledgebase in this area and, therefore, supplement and update the existing literature.

APC waivers and discounts are available for authors (especially early career scientists), and requests will be evaluated on a case-by-case basis.

Dr. Rushita Bagchi
Dr. Dipsikha Biswas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nutrients
  • amino acids
  • glucose
  • lipids
  • insulin
  • cardiometabolic
  • metabolism
  • signaling
  • trafficking
  • inter-organ crosstalk
  • cardiovascular diseases
  • insulin resistance
  • obesity
  • hypertension

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1828 KiB  
Article
Proteomic and Global DNA Methylation Modulation in Lipid Metabolism Disorders with a Marine-Derived Bioproduct
by Olaia Martínez-Iglesias, Vinogran Naidoo, Lola Corzo, Iván Carrera, Silvia Seoane, Susana Rodríguez, Margarita Alcaraz, Adriana Muñiz, Natalia Cacabelos and Ramón Cacabelos
Biology 2023, 12(6), 806; https://doi.org/10.3390/biology12060806 - 2 Jun 2023
Viewed by 2070
Abstract
Dyslipidemia is a significant risk factor for cardiovascular disease and stroke. Our recent findings showed that RCI-1502, a bioproduct derived from the muscle of the European S. pilchardus, has lipid-lowering effects in the liver and heart in high-fat diet (HFD) fed mice. In [...] Read more.
Dyslipidemia is a significant risk factor for cardiovascular disease and stroke. Our recent findings showed that RCI-1502, a bioproduct derived from the muscle of the European S. pilchardus, has lipid-lowering effects in the liver and heart in high-fat diet (HFD) fed mice. In the present follow-up study, we investigated the therapeutic potential of RCI-1502 on gene expression and DNA methylation in HFD-fed mice and in patients with dyslipidemia. Using LC-MS/MS, we identified 75 proteins in RCI-1502 that are primarily involved in binding and catalytic activity and which regulate pathways implicated in cardiovascular diseases. In HFD-fed mice, RCI-1502 treatment significantly reduced the expression of cardiovascular disease-related genes, including vascular cell adhesion molecule and angiotensin. RCI-1502 also decreased DNA methylation levels, which were elevated in HFD-fed mice, to levels similar to those in control animals. Furthermore, peripheral blood leukocyte DNA from dyslipidemic patients exhibited higher DNA methylation levels than healthy individuals, suggesting a potential association with cardiovascular risk. Serum analysis also revealed that RCI-1502 treatment regulated cholesterol and triglyceride levels in patients with dyslipidemia. Our findings appear to suggest that RCI-1502 is an epigenetic modulator for the treatment of cardiovascular diseases, specifically in individuals with dyslipidemia. Full article
Show Figures

Graphical abstract

Back to TopTop